Mazdutide and Orforglipron—New Evidence in Obesity and Diabetes

Glucagon-like peptide 1 (GLP-1) receptor agonists and other incretin-based medications, especially the newer-generation long-acting medications, have transformed the treatment of type 2 diabetes, obesity, and related cardiometabolic disorders with broad-spectrum efficacy that is above and beyond robust weight reduction. Once-weekly subcutaneous semaglutide, a GLP-1 receptor agonist, is currently approved by the US Food and Drug Administration (FDA) for long-term weight management, type 2 diabete...